In Vitro Diagnostic Collaboration and Licensing Deals 2016-2024
In Vitro Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024
In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 267 in vitro diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in in vitro diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading in vitro diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of in vitro diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of in vitro diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific in vitro diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in in vitro diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse in vitro diagnostic collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
In Vitro Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of in vitro diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.
In Vitro Diagnostic Collaboration and Licensing Deals includes:
• Trends in in vitro diagnostic dealmaking in the biopharma industry
• Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology
• The leading in vitro diagnostic deals by value
• Most active in vitro diagnostic licensing dealmakers
In Vitro Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse in vitro diagnostic collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in in vitro diagnostic dealmaking
2.1. Introduction
2.2. In vitro diagnostic deals over the years
2.3. Most active in vitro diagnostic dealmakers
2.4. In vitro diagnostic deals by deal type
2.5. In vitro diagnostic deals by therapy area
2.6. In vitro diagnostic deals by industry sector
2.7. Deal terms for in vitro diagnostic deals
2.7.1 In vitro diagnostic deals headline values
2.7.2 In vitro diagnostic deal upfront payments
2.7.3 In vitro diagnostic deal milestone payments
2.7.4 In vitro diagnostic royalty rates
Chapter 3 – Leading in vitro diagnostic deals
3.1. Introduction
3.2. Top in vitro diagnostic deals by value
Chapter 4 – Most active in vitro diagnostic dealmakers
4.1. Introduction
4.2. Most active in vitro diagnostic dealmakers
4.3. Most active in vitro diagnostic deals company profiles
Chapter 5 – In vitro diagnostic contracts dealmaking directory
5.1. Introduction
5.2. In vitro diagnostic contracts dealmaking directory
Chapter 6 – In vitro diagnostic dealmaking by technology type
Deal directory
Deal directory – In vitro diagnostic deals by company A-Z
Deal directory – In vitro diagnostic deals by deal type
Deal directory – In vitro diagnostic deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: In vitro diagnostic deals since 2016
Figure 2: Active in vitro diagnostic dealmaking activity – 2016 - 2024
Figure 3: In vitro diagnostic deals by deal type since 2016
Figure 4: In vitro diagnostic deals by therapy area since 2016
Figure 5: In vitro diagnostic deals by industry sector since 2016
Figure 6: In vitro diagnostic deals with a headline value
Figure 7: In vitro diagnostic deals with an upfront value
Figure 8: In vitro diagnostic deals with a milestone value
Figure 9: In vitro diagnostic deals with a royalty rate value
Figure 10: Top in vitro diagnostic deals by value since 2016
Figure 11: Most active in vitro diagnostic dealmakers 2016 - 2024
Figure 12: In vitro diagnostic deals by technology type since 2016
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted PDF)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
2cureX, 3a-diagnostics, 3M, 10X Genomics, 23andMe, Abbott Laboratories, Abingdon Health, Abionic, Accurate Diagnostic Laboratories, Actelion, Adaptive Phage Therapeutics, Adeptrix, Aegea Biotechnologies, AEYE Health, Afero, Africa Centres for Disease Control and Prevention, Africa Medical Supplies Platform, Africa Union, Agena Bioscience, Agendia, Agilent Technologies, AIMA Laboratories, Akribis Systems, Alexion Pharmaceuticals, Algenex, AliveCor, AllerGenis, Allogene Therapeutics, Alveo Technologies, A Menarini Diagnostics, American Type Culture Collection (ATCC), AMS, Amydis, Anixa Biosciences, ANP Technologies, Anteo Diagnostics, Apollon Formularies, Applied DNA Sciences, Appriss Health, Aptagen, Aptitude Medical Systems, Ares Genetics, Armed Forces Medical Research Institute, Arquer Diagnostics, Asieris MediTech, AssisTek, AstraZeneca, Asuragen, Atomo Diagnostics, Avacta, Avalon GloboCare, AvantGen, Avrobio, Babson Diagnostics, Banyan Biomarkers, BASF, Battelle, Baxter International, Bayer, BBI Solutions, Beckman Coulter, Becton Dickinson, Beth Israel Deaconess Medical Center, Bill and Melinda Gates Foundation, Binx Health, Bio-Rad Laboratories, Bio-Techne, bioAffinity Technologies, BioCanna Healthcare, Biocartis, Biocept, BioGen Medical, BioGX, BioIQ, Biokit, BioLight, BioMarker Strategies, Biomedical Advanced Research and Development Authority, BIOMEDX Group, bioMerieux, BioSyntagma, Biotage, Bioventix, Bird Foundation, Bluejay Diagnostics, Boehringer Ingelheim Vetmedica, Brigham and Women's Hospital, Bristol-Myers Squibb, Bruker, Cambridge Consultants, CARB-X, Cardiff University, CardiNor, CareDx, Case Western Reserve University, Cellgen Diagnostics, CellSafe, Centene, Centers for Disease Control and Prevention, Centogene, Cepheid, CerTest Biotec, Cleveland Clinic, Clinical Genomics, Clinton Health Access Initiative, CLX Health, CND Life Sciences, Collective Medical, Columbia University, Companion Medical, Congenica, Corvium, CPT Medical, CQuentia, Cue Health, Curative, Cytiva, CytoVale, Cytox, Dako, DaRui Biotech, DeepVerge, Defense Advanced Research Projects Agency, Department of Defense, Department of Health and Human Services, Devyser Diagnostics, DexCom, DiaSorin, Diassess, Digital Diagnostics, Doping Control Center, Eisai, EKF Diagnostics (Germany), Ellume, Empatica, Enable Biosciences, Endocanna Health, Enzo Biochem, Epizyme, Erasmus University Medical Center, Eureka Eurostars, Eurofins LifeCodexx, European Commission, EverlyWell, Evogen, Exagen Diagnostics, Expedeon, Ez Sleep Technologies, Fapon Biopharma, Ferring Pharmaceuticals, Fio, FitBit, Fluxergy, Food and Drug Administration (FDA), Foresight Diagnostics, Fortelinea Software Systems, Foundation for Innovative New Diagnostics, Fujirebio Diagnostics, Fulgent Genetics, G42 Healthcare, GBS, Genentech, Geneseeq, Gennova Biopharmaceuticals, Genolution, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomoncology, GenScript Biotech, GensKey Medical Technology, George Washington University, Getein Biotech, Ginkgo BioWorks, Global Access Diagnostics, Global Dx, Global Good Fund, Global WholeHealth Partners, Glooko, Glytec, GNA Biosolutions, Greenfield Global, Group K Diagnostics, Guardant Health, Gyros Protein Technologies, Halodoc, Hamilton Robotics, Health Logic Interactive, Health Network Laboratories, HeartGenetics, HelixBind, Hememics Biotechnologies, Hemex Health, Henry M. Jackson Foundation, HepQuant, Hologic, Hoowaki, Horizon Europe, Horizon Therapeutics, Hoth Therapeutics, Hvidovre Hospital, ii Ventures, Illumina, ImmunArray, Imperial College London, Inagene Diagnostics, Infectolab Americas, Infinity BiologiX, Inivata, Innovation Zed, Innovative Health Diagnostics, Institut Curie, Insulet, Integrated Computer Solutions, Invitae, InVivoScribe, Ionis Pharmaceuticals, iRhythm Technology, Jan Medical, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Johns Hopkins University, Johnson & Johnson Innovation, Johnson & Johnson Vision, John Wayne Cancer Institute, Jubilant Radiopharma, Kantaro Biosciences, Kephera Diagnostics, KingMed Diagnostics, Kore, L1 Systems, Laboratory Corporation of America, Lark Technologies, LifeLabs Medical Laboratory Services, LightDeck Therapeutics, Liverpool School of Tropical Medicine, Living Heart Foundation, Livongo Health, Longhorn Vaccines and Diagnostics, Lucence, Lucid Diagnostics, Luminex, Lumiphore, LumiraDx, Lunaphore, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mass General Brigham, Maxim Biomedical, Mayo Clinic, MBio Diagnostics, MD Anderson Cancer Center, Medibio, Medical Marijuana, Medical Research Foundation, Medicinal Genomics, Medigus, Meenta, Meihua International Medical Technologies, MeMed, Memorial Sloan Kettering Cancer Center, Meridian Bioscience, Mesa Biotech, Metafora Biosystems, Methapharm, MicrobeDx, Microdrop, MicroGEM, Minnesota Health System, Mirimus, Mologic, Monsanto, Motic, Mount Sinai Health System, MyHealthChecked, Mylan Laboratories, Nanommune, NanoMosaic, NanoPin Technologies, Narayana Nethralaya Foundation, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Aging, National Institutes of Health, National Research Council Canada, National Science Foundation, Navidea Biopharmaceuticals, Navy Medical Research Centre, Nemaura Medical, Neogen, Nephron Pharmaceuticals, Neurotrack, New Jersey Urology, Newly Institute, NGeneBio, Nicoya, Nimble Therapeutics, Novartis, Novoheart, NOWDiagnostics, Nucleix, Numares, Ohio State Innovation Foundation, Ohio State University, Oklahoma Medical Research Foundation, Olive Labs, OmeCare, Omega Diagnostics Group, Omixon, OmniPathology, One Drop, Ontera, Operon Technologies, OraSure Technologies, OrigiMed, Ortho-Clinical Diagnostics, Osteolabs, Otsuka, Owlstone Medical, Oxford Immunotec, Oxford Nanopore Technologies, Oxgene, PAI, Pan Probe Biotech, PAVmed, PerkinElmer, Personal Genome Diagnostics, Perspectum Diagnostics, Pfizer, Phosphorus Genomics, Photocure ASA, Pillar Biosciences, Precision Biomonitoring, PredictImmune, Prescient Medical, Prevencio, Primary Bio, ProciseDx, Progentec Diagnostics, Providence Saint John's Health Center, Public Health England, Q-linea AB, Qiagen, QMC HealthID, Quanterix, QuantumDx, Quest Diagnostics, Quidel, Rapid Dx Laboratory, Relay Medical, RenalytixAI, Renegade Bio, Revon Systems, Roche, Roche Diagnostics, Roche Molecular Systems, Royal Philips Electronics, Saladax Biomedical, Sansure Biotech, Scanwell Health, Seattle Childrens Research Institute, Sebia, Seegene, Senseonics, Sensible Medical Innovations, Sensifree, Seventh Sense Biosystems, Shandong Yingsheng Biotechnology, Sherlock Biosciences, Siemens Healthineers, SkylineDX, Sona Nanotech, Sorrento Therapeutics, SpeeDx, SQI Diagnostics, Stanford University, Stellar Technologies, St Georges University of London, Stone Diagnostics, Stony Brook University, Strados Labs, Sumocor, Symcel, SystemOne, Takara Bio USA, Talis Biomedical, Tangen Biosciences, Tauriga Sciences, TBG Management, Techcyte, Tempus, The Native Antigen Company, Theradiag, Therma Bright, Thermo Fisher Scientific, Tika Diagnostics, Topcon, Total Testing Solutions, TPMENA, Tried & Tested, True Diagnostics, Tulane University, Two Pore Guys, U-Diagnostics, U.K. Department for International Development, Ubiquitome, UCB, United States Agency for International Development, University College London, University Hospital of Leuven, University of Arkansas, University of Glasgow, University of Ottawa, University of Oxford, University of Sunderland, University of Surrey, University of Texas Health SCience Center at San Antonio, US Army, Vault Health, Vela Diagnostics, Velox Biosystems, Veracyte, Veravas, Verily, Virex Health, Visby Medical, VisionQuest Biomedical, Visualant, Vivera Pharmaceuticals, VolitionRX, Volk Optical, VOTIS Subdermal Imaging Technologies, Wellcome Trust, WinterLight Labs, Woom, Wuhan Kindstar Diagnostics, WuXi Biologics, Wyss Institute, XPhyto Therapeutics, Yale School of Medicine, Yale University, Zora Biosciences, zPREDICTA, Zymo Research
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
